These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 17082926)

  • 1. [What kind of stone prevention for whom? Risk-adjusted metaphylaxis following urinary stone disease].
    Straub M
    Urologe A; 2006 Nov; 45(11):1387-8, 1390-1. PubMed ID: 17082926
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Evidence-based pharmacological metaphylaxis of stone disease].
    Straub M; Hautmann RE
    Urologe A; 2006 Nov; 45(11):1399-400, 1402-5. PubMed ID: 17119896
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Modern general metaphylaxis of stone disease. New risks, new evidence, new recommendations].
    Siener R; Hesse A
    Urologe A; 2006 Nov; 45(11):1392, 1394-8. PubMed ID: 17068668
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Economic aspects of evidence-based metaphylaxis].
    Strohmaier WL
    Urologe A; 2006 Nov; 45(11):1406-9. PubMed ID: 17063349
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolic evaluation and recurrence prevention for urinary stone patients: EAU guidelines.
    Skolarikos A; Straub M; Knoll T; Sarica K; Seitz C; Petřík A; Türk C
    Eur Urol; 2015 Apr; 67(4):750-63. PubMed ID: 25454613
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnosis and metaphylaxis of stone disease. Consensus concept of the National Working Committee on Stone Disease for the upcoming German Urolithiasis Guideline.
    Straub M; Strohmaier WL; Berg W; Beck B; Hoppe B; Laube N; Lahme S; Schmidt M; Hesse A; Koehrmann KU
    World J Urol; 2005 Nov; 23(5):309-23. PubMed ID: 16315051
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The dilemma of metaphylaxis of urinary calculi].
    Zechner O
    Wien Med Wochenschr; 1995; 145(11-12):279-82. PubMed ID: 7571652
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rational evaluation of urinary stone disease.
    Hesse A; Straub M
    Urol Res; 2006 Apr; 34(2):126-30. PubMed ID: 16450128
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Current state of metaphylaxis of urinary stones in Russian Federation].
    Malkhasyan VA; Gazimiev MA; Martov AG; Gadzhiev NK; Sukhikh SO; Pushkar DY
    Urologiia; 2022 Nov; (5):46-52. PubMed ID: 36382817
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metaphylaxis of urolithiasis.
    Menditto VG; Milanese G; Muzzonigro G
    Arch Ital Urol Androl; 2009 Mar; 81(1):32-9. PubMed ID: 19499756
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Socioeconomic aspects of urinary calculi and metaphylaxis of urinary calculi].
    Strohmaier WL
    Urologe A; 2000 Mar; 39(2):166-70. PubMed ID: 10768228
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Renal stone disease in children.
    Santos-Victoriano M; Brouhard BH; Cunningham RJ
    Clin Pediatr (Phila); 1998 Oct; 37(10):583-99. PubMed ID: 9793728
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Urinary stone disease. Part IV. Recurrence prevention for urinary stone disease].
    Saenko VS; Gazimiev MA; Pesegov SV; Alyaev YG
    Urologiia; 2019 Jun; (2):88-96. PubMed ID: 31162908
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Adjustment of urine PH as effective tool for successful metaphylaxis of urinary stone disease. phytotherapy].
    Saenko VS; Lachinov EL; Zhantlisov DA; Gorbachev MI; Soltanov AA
    Urologiia; 2020 Jun; (3):104-110. PubMed ID: 32597596
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of n-3 fatty acid supplementation on urinary risk factors for calcium oxalate stone formation.
    Siener R; Jansen B; Watzer B; Hesse A
    J Urol; 2011 Feb; 185(2):719-24. PubMed ID: 21168878
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dietary treatment of urinary risk factors for renal stone formation. A review of CLU Working Group.
    Prezioso D; Strazzullo P; Lotti T; Bianchi G; Borghi L; Caione P; Carini M; Caudarella R; Ferraro M; Gambaro G; Gelosa M; Guttilla A; Illiano E; Martino M; Meschi T; Messa P; Miano R; Napodano G; Nouvenne A; Rendina D; Rocco F; Rosa M; Sanseverino R; Salerno A; Spatafora S; Tasca A; Ticinesi A; Travaglini F; Trinchieri A; Vespasiani G; Zattoni F;
    Arch Ital Urol Androl; 2015 Jul; 87(2):105-20. PubMed ID: 26150027
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolic evaluation and medical management of upper urinary tract stone disease. Guidelines from the Scandinavian Cooperative Group for Urinary Stones.
    Osther PJ; Grenabo L; Haraldsson G; Holmberg G; Lindell O; Mogensen P; Schultz A; Ulvik NM
    Scand J Urol Nephrol; 1999 Dec; 33(6):372-81. PubMed ID: 10636576
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glycosaminoglycans as inhibitors of stone formation.
    Sallis JD
    Miner Electrolyte Metab; 1987; 13(4):273-7. PubMed ID: 3306320
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical outcome of percutaneous nephrolithotripsy and recurrence of stones].
    Nakajima H; Tanda H; Kato S; Ohnishi S; Ujiie T; Nanbu A; Ando T
    Hinyokika Kiyo; 1997 Aug; 43(8):549-53. PubMed ID: 9310776
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Metaphylaxis of recurrent renal calcium stones].
    Pasch A
    Ther Umsch; 2007 May; 64(5):253-8. PubMed ID: 17685083
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.